Premium
Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results
Author(s) -
Ogawa Masahiro,
Takayasu Kentaro,
Hirayama Midori,
Miura Takao,
Shiozawa Katsuhiko,
Abe Masahisa,
Matsumoto Naoki,
Nakagawara Hiroshi,
Ohshiro Shu,
Yamamoto Toshiki,
Tanaka Naohide,
Moriyama Mitsuhiko,
Mutou Haruomi,
Yamamoto Yoshinobu,
Irie Toshiyuki
Publication year - 2016
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12527
Subject(s) - hepatocellular carcinoma , medicine , therapeutic effect , common terminology criteria for adverse events , adverse effect , gastroenterology , radiology
Aim The goal of the study was to evaluate the efficacy and safety of balloon‐occluded transarterial chemoembolization (B‐TACE) of hepatocellular carcinoma (HCC) using miriplatin (a lipophilic anticancer drug) and gelatin particles. Methods B‐TACE was performed for 62 HCC nodules in 33 patients who could not be treated by surgical resection or radiofrequency ablation. All 33 patients had a history of transarterial chemoembolization (TACE) treatment prior to B‐TACE. As a historical comparison, we investigated 40 nodules in 28 patients treated by TACE using a conventional microcatheter (C‐TACE), miriplatin and gelatin particles. The therapeutic effect per tumor was compared between the groups based on the Response Evaluation Criteria in Cancer Study Group of Japan (RECICL) and side‐effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0). Results The therapeutic efficacy after 4–12 weeks was evaluated in 59 nodules in the B‐TACE group and in 37 nodules in the C‐TACE group. Of these nodules, TE4 occurred in 29 (49.2%) in the B‐TACE group and in 10 (27%) in the C‐TACE group. Local efficacy was significantly higher in nodules treated by B‐TACE than by C‐TACE. The side‐effects on hepatic function were similar in the two groups. Conclusion Our results suggest that B‐TACE with miriplatin is a useful treatment for hepatocellular carcinoma.